N4 Pharma Management
Management criteria checks 2/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Key information
Nigel Theobald
Chief executive officer
UK£77.5k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 10.3yrs |
| CEO ownership | 6.3% |
| Management average tenure | 4.9yrs |
| Board average tenure | no data |
Recent management updates
Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?
Mar 18
Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay
Mar 01Recent updates
Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth
Oct 11Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation
Jul 06Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?
Mar 18Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay
Mar 01Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth
Dec 07
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -UK£925k |
| Mar 31 2023 | n/a | n/a | -UK£977k |
| Dec 31 2022 | UK£78k | UK£78k | -UK£1m |
| Sep 30 2022 | n/a | n/a | -UK£1m |
| Jun 30 2022 | n/a | n/a | -UK£1m |
| Mar 31 2022 | n/a | n/a | -UK£1m |
| Dec 31 2021 | UK£75k | UK£75k | -UK£2m |
| Sep 30 2021 | n/a | n/a | -UK£2m |
| Jun 30 2021 | n/a | n/a | -UK£2m |
| Mar 31 2021 | n/a | n/a | -UK£2m |
| Dec 31 2020 | UK£72k | UK£72k | -UK£1m |
| Sep 30 2020 | n/a | n/a | -UK£1m |
| Jun 30 2020 | n/a | n/a | -UK£863k |
| Mar 31 2020 | n/a | n/a | -UK£869k |
| Dec 31 2019 | UK£70k | UK£70k | -UK£876k |
| Sep 30 2019 | n/a | n/a | -UK£1m |
| Jun 30 2019 | n/a | n/a | -UK£1m |
| Mar 31 2019 | n/a | n/a | -UK£1m |
| Dec 31 2018 | UK£70k | UK£70k | -UK£1m |
Vergütung im Vergleich zum Markt: NigelDie Gesamtvergütung ($USD97.24K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD348.41K).
Entschädigung vs. Einkommen: NigelDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
CEO
Nigel Theobald (59 yo)
10.3yrs
Tenure
UK£77,500
Compensation
Mr. Nigel James Theobald has been Chief Executive Officer of N4 Pharma Plc since May 3, 2017 and serves as its Executive Director. Mr. Theobald served as the Head of Emerge Marketing Ltd., for Alltracel Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.3yrs | UK£77.50k | 6.32% £ 123.1k | |
| Executive Director & Technical Director | 4.9yrs | UK£51.04k | no data | |
| Executive Director | 3.8yrs | UK£45.87k | 0.053% £ 1.0k | |
| Head of CMC Development | 4.2yrs | no data | no data | |
| Consultant | 5.3yrs | no data | no data |
4.9yrs
Average Tenure
59yo
Average Age
Erfahrenes Management: N4PDas Führungsteam des Unternehmens gilt als erfahren (4.6 Jahre durchschnittliche Betriebszugehörigkeit).